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The thrombopoietin receptor (TpoR) is a type I transmembrane protein that mediates the
signaling functions of thrombopoietin (Tpo) in regulating megakaryocyte differentiation,
platelet formation, and hematopoietic stem cell renewal. We probed the role of each of
the four extracellular domain putative N-glycosylation sites for cell surface localization and
functionofthereceptor.SingleN-glycosylationmutantsatanyofthefoursiteswereableto
acquirethematureN-glycosylatedpattern,butexhibitedadecreasedTpo-dependentJAK2–
STAT response in stably transduced Ba/F3 or Ba/F3-JAK2 cell lines.The ability of JAK2 to
promote cell surface localization and stability ofTpoR required the ﬁrst N-glycosylation site
(Asn117).Incontrast,thethirdN-glycosylationsite(Asn298)decreasedreceptormaturation
and stability. TpoR mutants lacking three N-glycosylation sites were defective in matura-
tion, but N-glycosylation on the single remaining site could be detected by sensitivity to
PNGaseF .TheTpoR mutant defective in all four N-glycosylation sites was severely impaired
in plasma membrane localization and was degraded by the proteasome. N-glycosylation
receptor mutants are not misfolded as, once localized on the cell surface in overexpression
conditions, they can bind and respond toTpo. Our data indicate that extracellular domain
N-glycosylation sites regulate in a combinatorial manner cell surface localization ofTpoR.
WediscusshowmutationsaroundTpoRN-glycosylationsitesmightcontributetoinefﬁcient
receptor trafﬁc and disease.
Keywords: cytokine receptor, thrombopoietin, JAK2, N-glycosylation, signal transduction, endoglycosidase H,
ER maturation, cell surface trafﬁc
INTRODUCTION
The thrombopoietin receptor (TpoR) is a major regulator of
megakaryopoiesis and of platelet formation, and is required for
maintaining the quiescence of hematopoietic stem cells, regu-
lating proliferation of early myeloid progenitors and removal
of circulating thrombopoietin (Tpo) ligand from blood by cir-
culating platelets (Kaushansky et al., 1994; Solar et al., 1998).
TpoR is an N-glycosylated, single-pass transmembrane protein
with the N-terminus in the extracellular space. It belongs to the
homodimeric type I cytokine receptor subfamily, which includes
the receptors for erythropoietin (Epo), granulocyte-colony stim-
ulating factor (GCSF), growth hormone (GH), and prolactin
(Prl; Vigon et al., 1992, 1993; Skoda et al., 1993; Drachman and
Kaushansky, 1995). Proper folding and trafﬁc to cell surface are
crucial for these cytokine receptors to receive signals from their
cognate cytokines. TpoR lacks intrinsic kinase activity and relies
on the cytokine-dependent activation of the cytoplasmic non-
receptor Janus kinase (JAKs) family proteins that are bound to
their intracellular domains (Drachman et al., 1995; Ezumi et al.,
1995), with JAK2 being the main kinase required for receptor
effects(Drachmanetal.,1999).Tpostimulationof thecellsurface
Abbreviations: CAMT, congenital amegakaryocytic thrombocytopenia; FT, famil-
ial thrombocytosis; JAK, Janus kinase; STAT, signal transducers and activators of
transcription; TpoR, thrombopoietin receptor.
localized TpoRs results in trans-phosphorylation of TpoR-bound
JAKs and the subsequent activation of several downstream path-
ways, including the signal transducer and activator of transcrip-
tion5(STAT5),STAT3,Ras/mitogen-activatedproteinkinase,and
phosphatidylinositol-3 -kinase/AKT (Miyakawa et al.,1995,1996;
Onishi et al., 1996).
The type I hematopoietic cytokine receptor family, of which
TpoR is a member, consists of more than 10 members that bear
oneortwocytokinereceptormotifs(CRM),anapproximately200
aminoacid module, containing four spatially conserved cysteine
residues, 14 beta-sheets and a juxtamembrane Trp-Ser-X-Trp-Ser
conserved sequence required for receptor folding and intracellu-
lar trafﬁc (Bazan, 1990; Yoshimura et al., 1992). All mammalian
TpoRs contain duplications of the CRM domains, when com-
pared to other receptors of the family such as the EpoR, or
human prolactin receptor (hPrlR). The two TpoR CRMs can be
divided in four sub-domains of approximately 100 aminoacids
(namely D1D2 for the distal, N-terminal CRM and D3D4 for
the proximal, C-terminal CRM), each showing homologies with
the ﬁbronectin type III module (Figure 1B). Structural model-
ing and ligand binding afﬁnity experiments showed that D1D2
is responsible for the Tpo binding (Deane et al., 1997; Feese
et al., 2004; Figure 1B) and possibly for preventing the rest of
the receptor to signal in the absence of ligand (Sabath et al.,
1999).
www.frontiersin.org November 2011 | Volume 2 | Article 71 | 1Albu and Constantinescu N-glycosylation controlsTpoR surface localization
FIGURE1|S c hematic representation of humanTpoR and
multiple sequence alignment of the N-glycosylation sites of
TpoR from different species. (A) Multiple sequence alignment
showing conservation of the ﬁrst N-glycosylation site from different
species.The alignment was obtained with the ClustalW program for
the following sequences: Homo sapiens (UniProtKB/Swiss-Prot
accession number P40238), Mus musculus (Q08351), Rattus
norvegicus (D4A2R0), Gallus gallus (Q6IYE8), Danio rerio (Q6EIY6).
The positions of the four putative N-glycosylation sites of human
TpoR are depicted. (B) Schematic representation of humanTpoR.
The bottom panel of (B) depicts the D1D2 cytokine receptor
module.The important aminoacids forTpo binding are underlined
(Deane et al., 1997). In square () are depicted the aminoacids that
are mutated in congenital amegakaryocytic thrombocytopenia
(Ballmaier et al., 2001; Germeshausen et al., 2006;Tijssen et al.,
2008; Fox et al., 2009) and in round circles ( ) the aminoacids that
are mutated in familial thrombocytosis (Moliterno et al., 2004;
El-Harith El et al., 2009).TM, transmembrane region; aa, aminoacid;
D1D2, sub-domains of the distal cytokine receptor module; D3D4,
sub-domains of the proximal cytokine receptor module; NH2,
N-terminus of the protein; COOH, C-terminus of the protein; X, any
aminoacid.
Little is known about regulation of TpoR trafﬁc to the cell
surface or about the mechanisms that govern receptor internal-
ization, degradation, and recycling. On the cytosolic side, JAK2
and TYK2 were shown to promote cell surface localization and
stabilityofTpoR(Royeretal.,2005),buttheextracellulardetermi-
nants of endoplasmic reticulum (ER) to cell surface trafﬁc remain
unknown.
The role of extracellular domain N-glycosylation for cytokine
receptortrafﬁcremainsdebated.N-glycosylationisapparentlynot
required for induction of gene transcription via PrlR and gp130,
but is crucial for receptors’ stability and cell surface localiza-
tion (Buteau et al., 1998; Bolander, 1999; Waetzig et al., 2010).
On the other hand, in the case of leptin and GM-CSF recep-
tors, N-glycans are important for ligand binding (Ding et al.,
1995; Niu et al., 2000; Kamikubo et al., 2008). Eliminating indi-
vidual N-glycans in human β-common subunit of the IL3, IL5,
and GM-CSF receptors did not affect ligand binding and recep-
tor activation, but the authors did not exclude the possibility
that N-glycans may exert some sort of ﬁne control (Murphy
et al., 2008). TpoR presents four putative N-glycosylation sites in
its extracellular domain, two in each cytokine receptor module
(Figure 1). In this study we aimed to probe the role of each
N-glycosylation site in the cell surface expression and function
of TpoR.
MATERIALS AND METHODS
PLASMIDS AND GENERATION OF HUMAN TpoR N-GLYCOSYLATION
DEFECTIVE VARIANTS
The human TpoR wild-type (WT) was cloned into the pMX-
IRES-GFP bicistronic retroviral vector upstream of the IRES as
described (Liu et al., 2000). Several mutagenesis reactions with
speciﬁcprimerswerecarriedoutonhumanTpoRWT(Swiss-Prot
accession number P40238) with the QuickChange Site-Directed
Mutagenesis Kit (Stratagene). Human TpoR variants lacking sin-
gle N-glycosylation sites were obtained by changing the codon
for Asn (AAC or AAT) to the codon for Gln (CAA) in each of
the four potential N-glycosylation sequons. The resulting pro-
teins were named (Δ (1), Δ (2), Δ (3), and Δ (4), respectively,
according to the particular N-glycosylation site that was removed
(Table 1). Other mutants lacking more than one N-glycosylation
site were obtained leaving only one N-glycosylated site: (Δ (123),
(Δ(134),(Δ(124),(Δ(234)(Table 1).Allconstructswereveriﬁed
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Table 1 | Name and description of the engineered humanTpoR
variants.
Name of
TpoR variant
Mutated
N-glycosylation sites*
Remaining
N-glycosylation sites*
Δ (1234) N117 , N178, N298, N358 –
Δ (1) N117 N178, N298, N358
Δ (2) N178 N117 , N298, N358
Δ (3) N298 N117 , N178, N358
Δ (4) N358 N117 , N178, N298
Δ (123) N117 , N178, N298 N358
Δ (124) N117 , N178, N358 N298
Δ (134) N117 , N298, N358 N178
Δ (234) N178, N298, N358 N117
*Residue number for the Asn in the Asn-X-Ser/Thr sequon, TPOR_HUMAN,
Swiss-Prot accession number P40238.
by sequencing. All TpoR constructs contain an HA tag at their N-
terminus, after the signal peptide cleavage site. The murine JAK2
WT was subcloned into the pREX-IRES-CD4 vector.
GENERATION OF CELL LINES AND RETROVIRAL TRANSDUCTIONS
HEK293-derived BOSC cells are ecotropic retrovirus packaging
cells (Pear et al., 1993). γ2A are JAK2-deﬁcient human ﬁbrosar-
coma cells (Pellegrinietal.,1989).Ba/F3parentalandBa/F3-JAK2
cells are IL3-dependent murine pro-B cells (Palacios and Stein-
metz, 1985). Ba/F3-JAK2 is a stably transduced cell line with
murine JAK2 WT (Royer et al., 2005) in order to have increased
levels of JAK2 (approximately ﬁvefold higher JAK2 levels than the
endogenous JAK2 levels of Ba/F3 cells).
StablytransducedBa/F3orBa/F3-JAK2celllineswereobtained
for each TpoR variant. Typically, high titer replication-defective
retroviralsupernatantsweregeneratedbyLipofectaminetransient
transfection of BOSC packaging cells using standard protocols
(Seubert et al., 2003). The viruses were used to stably transduce
2×106 cells by centrifugation at 1,300rpm, at 37˚C for 3h in the
presenceof 4μg/mlPolybrene(Sigma).Althoughtheefﬁciencyof
infection was around 30–50%, populations of cells expressing the
same level of marker,GFP were isolated by ﬂuorescence-activated
cell sorter (FACS) 72h after infection and cultured in IL3.
DUAL LUCIFERASE ASSAYS
The STAT5 and STAT3 transcriptional activities of the vari-
ous mutants were measured in γ2A or HEK293 cells by dual
luciferase assays with the STAT reporters, pGRR5-luc or pLHRE-
luc(Dumoutieretal.,2000;Gerlandetal.,2000).pGRR5-luccon-
tainsﬁvecopiesoftheSTAT-bindingsiteoftheFcγRIgeneinserted
upstream of a luciferase gene under the transcriptional control of
thethymidinekinase(TK)promoter.pLHRE-lucharborstandem
copies of the STAT5-inducible lactogenic hormone response ele-
ment(LHRE)oftheratβ-caseingenepromoter,insertedupstream
a luciferase gene. As an internal control, we used pRLTK-luc vec-
tor that contains the Renilla luciferase gene under the control of
the TK promoter. Brieﬂy, cells were seeded in 24-well plates with
24h before being transfected. The transfection was performed
using Lipofectamine (Invitrogen), with pGRR5-luc, pRLTK-luc,
and the cDNA coding for each individual TpoR mutant, if not
mentioned otherwise (in some cases the cDNA of human JAK2
WT was added). Empty vector was added in order to normalize
the total transfected cDNA. Four hours after transfection the cells
were stimulated with recombinant human Tpo (R&D System) or
left unstimulated for 20h. Twenty-four hours after transfection,
cells were lysed in 100μl1 × passive lysis (Promega) and lumi-
nescence was recorded on a Glomax 96-well plate luminometer.
When performing the assay on Ba/F3 or Ba/F3-JAK2 cells (also
stably expressing each human TpoR mutant), cells were starved
3–4h in RPMI medium with 1mg/ml BSA, and electroporated
(250V, 75Ω, 1,500μF) with the pGRR5 and pRLTK luciferase
reporters. The cells were subsequently cultured for 2h, stimu-
lated with recombinant human Tpo (rhTpo, R&D System) or IL3
or left unstimulated. After 2h, the cells were lysed in 100μl1 ×
passive lysis buffer and their luminescence was recorded. All the
luciferaseassayswereperformedusingthedualluciferasereporter
kit (Promega).
Tpo-DEPENDENT PROLIFERATION ASSAY
Three thousand stably transduced Ba/F3 cells were seeded in
96-well plates and stimulated with different concentrations of
rhTpo, or mock. Control for proliferation was performed using
10ng IL3/ml for each cell line. After 72h, tritiated thymidine was
added to the cells for 4h. Cells were then collected on micro-
ﬁltered plates, and thymidine incorporation was measured with
Top Count microplate scintillation counter (Canberra-Packard,
Meriden, CT, USA).
SURFACE EXPRESSION OF HA TAGGED TpoR MUTANTS
Surface expression of the receptors was measured in 10×106
Ba/F3, Ba/F3-JAK2, or HEK293 cells by ﬂow cytometry using
10μg/ml monoclonal anti-HA antibody (HA.11, Covance) and
5μg/ml R-phycoerythrin-conjugated donkey F(ab ) anti-mouse
IgG secondary antibody (Jackson ImmunoResearch; Huang et al.,
2001).
WESTERN BLOTTING, ENDOGLYCOSIDASE-H (ENDOH), AND
N-GLYCOSIDASE F (PNGaseF) DIGESTION
Ba/F3, Ba/F3-JAK2, or HEK293 cells expressing stably or tran-
siently each human TpoR mutant were washed in cold PBS,
lysed in 200μl Nonidet P-40 buffer with sodium orthovanadate,
sodium ﬂuoride, phenylmethanesulfonyl ﬂuoride, and complete
protease inhibitor cocktail (Roche Applied Science). Cell lysates
were digested with EndoH or PNGaseF (both from New Eng-
land BioLabs) or left untreated for 16h at 37˚C. The lysate
supernatants/products of the digestions were then mixed with
Laemmli Blue 4×, boiled for 10min, and centrifuged for 1min
at 14,000rpm. A volume equivalent to 30μg protein/well was
loadedon4–12%BisTrisprecastgels(Invitrogen).Aftertransferto
nitrocellulose membranes and blocking in 20% milk/TBS–Tween,
immunoblotting was performed overnight at 4˚C with mouse
anti-HA tag (HA.11, Covance), mouse anti-β-actin (Sigma), or
rabbit anti-JAK2 (Cell Signaling) antibodies in a solution of 3%
milk/TBS–Tween with a 1:1,000 antibody dilution. Secondary
mouse or rabbit-horseradish peroxidase antibodies (GE Health-
care,UK)wereusedina1:10,000dilutionin3%milk/TBS–Tween.
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MEASUREMENTS OF TpoR MUTANT HALF-LIFE AND DEGRADATION
For measuring the contribution of the proteasome- or lysosome-
mediated degradation of the TpoR N-glycosylation defective
mutant Δ (1234) versus WT, stably transduced Ba/F3 or Ba/F3-
JAK2cellswereincubated3hat37˚Cwith50μg/mlcycloheximide
(Sigma; to block protein synthesis) and proteasome inhibitor
MG132 (10μM; Sigma) or with 50μg/ml cycloheximide and
lysosome inhibitors (200μM chloroquine or 10μg/ml leupeptin;
Roche). Control cells were kept untreated to have 100% protein
expression.CellswerelysedandanalyzedbyWesternblottingwith
antibodies anti-HA for TpoR levels.
The half-life measurements of different TpoR variants were
determined by treating the Ba/F3 stably transduced cell lines with
50μg/mlcycloheximidefordifferenttimelengths.Cellswerethen
lysed and analyzed by Western blotting with antibodies anti-HA
for the levels of immature and mature TpoR. Anti-β-actin was
used as a control.
RESULTS
HUMAN TpoR CELL SURFACE LEVELS AND ACTIVITY ARE NOT
CRITICALLY DEPENDENT ON INDIVIDUAL N-GLYCOSYLATION
The ﬁrst question of our study was whether there is a single crit-
ical N-glycosylation site of human TpoR that is responsible for
the efﬁciency of cell surface localization. Taking into account that
JAK2 is able to promote cell surface localization and to increase
TpoRproteinstabilityintheBa/F3cellline(Royeretal.,2005),we
assessed cell surface levels of single N-glycosylation mutant TpoR
variants in Ba/F3 cells with endogenous or elevated JAK2 levels.
Thrombopoietin receptor mutants lacking one out of four
putative N-glycosylation sites (Figure 1; Table 1) were obtained
by using site-directed mutagenesis on a human TpoR WT tem-
plate,andthenclonedintothebicistronicvector,pMX-IRES-GFP.
The constructs were then used to produce retroviral supernatants
in HEK293-derived BOSC cells. The retroviral supernatants were
subsequentlyutilizedtoinfectmurineBa/F3cellsexpressingornot
increased levels of murine JAK2WT (cloned in bicistronic pREX-
IRES-CD4 vector). To avoid clone-speciﬁc artifacts in expression
orsignaltransduction,stablytransducedBa/F3cellpools,withthe
samelevelofTpoRconstructexpressionwereused.Moreprecisely,
the cells were sorted for similar GFP levels 72h later (correlated
withthesamemRNAlevelforeachTpoRvariant).Sortedcelllines
were lysed and the protein for each TpoR variant was analyzed for
thecorrectmolecularsizeusinganti-HAinWesternblotting(data
not shown).
Flow cytometry using HA.11 antibody performed in Ba/F3 cell
lines exhibiting equivalent GFP expression consistently showed
that, compared with the WT receptor, Δ (1) cell surface local-
ization was decreased, while Δ (3) cell surface localization was
increased (Figure 2A). In the Ba/F3-JAK2 cell line, the four
variants lacking single N-glycosylation site are expressed at the
same level [Δ (2), (Δ (3), Δ (4)] or lower, as is the case for
Δ (1) (Figure 2A). We also transiently expressed these variants
in HEK293 cells, achieving overexpression. Also in these condi-
tionsΔ(1)cellsurfacelocalizationwasdecreased,whileΔ(3)cell
surface localization was increased (data not shown).
The ﬂow cytometry results were veriﬁed by Western blots
experiments,whereweenzymaticallyanalyzedtheN-glycosylation
FIGURE2|E f f e c to fsingle N-glycosylation site removal on the cell
surface levels and stability of humanTpoR. (A) Sorted Ba/F3 parental or
Ba/F3-JAK2 cells, expressingTpoR variants defective in one N-glycosylation
site [Δ (1), Δ (2), Δ (3), Δ (4)] were tested for cell surface levels using
anti-HA antibody based ﬂow cytometry. Similar results were obtained in
four independent experiments, on two different cell lines obtained for each
TpoR variant.The differences between the cell surface levels of Δ (1)TpoR
in Ba/F3 and Ba/F3-JAK2 cells were statistically signiﬁcant when compared
with the levels of WTTpoR (p =0.006 and p =0.0086, respectively). (B)
HEK293 cells were plated in 6-well plates and transiently transfected with
3μg of each of the indicatedTpoR variants.Twenty-four hours
post-transfection cells were lysed and treated with EndoH or PNGaseF or
left untreated and subjected to Western blot analysis. Membranes were
probed with anti-HA. Similar results were obtained in three different
experiments. (C) A pool of the cell lines used in (A) were treated at 37˚C
with 50μg/ml cycloheximide (CHX) over different time periods then lysed.
The lysates were analyzed forTpoR variants stability using anti-HA and
normalizing by anti-β-actin Western blotting.
pattern. The fact that all the TpoR variants defective in single N-
glycosylationsiteareabletolocalizeatthecellsurfaceisconﬁrmed
inFigure2B.WeshowedintheHEK293celllinethatthesevariants
presented a strong EndoH resistant band, which correlated with
the mature form of each variant. When the ﬁrst N-glycosylation
site is removed, the level of the mature receptor band seems to
be weaker compared with the mature band of the WT, correlat-
ing very well with the decreased cell surface localization for this
mutant.
To test whether the cell surface receptors defective in single N-
glycosylation site are as stable as the WT TpoR, we used Ba/F3
cells stably transduced with each of the mutants. The cells were
treated with CHX (cycloheximide) over different time periods, in
ordertoblockproteinsynthesisanddeterminethehalf-lifeof each
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TpoRvariantbyusinganti-HAandanti-β-actinWesternblotting.
Compared with the WT, Δ (3) TpoR showed higher and Δ (1)
TpoR lower stability (Figure 2C), which correlated well with the
cell surface level differences.
We were interested to determine the relevance of each of
the N-glycans for the TpoR function. For each of the human
TpoR variants lacking one N-glycosylation site, we assessed the
STAT3 and STAT5 transcriptional activities using luciferase assays
in stably transduced Ba/F3 or Ba/F3-JAK2 cell models. These
TpoR variants presented a decreased transcriptional activity in
the Tpo-stimulated condition, compared with the WT TpoR
(Figure 3A). Between the TpoR variants the levels of Tpo-
dependent transcriptional activity correlated well with the cell
surface levels of the TpoR variants, with Δ (1) having the
lowest and Δ (3) the highest Tpo-dependent transcriptional
activity.
Our preliminary observation was that Tpo binding to TpoR
is not critically dependent on individual N-glycosylation sites. To
test this observation in a second set of experiments, we measured
Tpo-dependent cell growth of Ba/F3 stably transduced with each
of the TpoR variant. Cells were washed to remove IL3, incubated
72h in Tpo or IL3 or left untreated.As a negative control,we used
Ba/F3cellswithoutanyTpoRvariant.Asapositivecontrolforcell
growth, we used IL3 treatment of each cell line. After 72h, triti-
ated thymidine was added to the cells for 4h. The proliferation of
the cells was quantiﬁed according to the level of the incorporated
thymidine (Figure 3B). The order of the cell proliferation level
was Δ4>Δ3=WT>(Δ2>Δ1 and the result is consistent with
the result obtained in the luciferase test of Figure 3A.
REMOVAL OF THREE N-GLYCOSYLATION SITES DECREASED CELL
SURFACE LEVELS AND ACTIVITY OF HUMAN TpoR
The Ba/F3 and Ba/F3-JAK2 cells were stably transduced with the
variants missing different combinations of N-glycosylation sites
(Table 1). The cells were sorted for the same protein expres-
sion level for each TpoR variant and tested for cell surface
expression of the receptors. All of the variants, with only one
N-glycosylation site left [Δ (123), Δ (124), (Δ (134), Δ (234)]
were located at a lower level at the cell surface,compared with the
WT TpoR (Figure 4A). JAK2 overexpression did not increase the
cell surface level of these variants. We also tested the cell sur-
face levels of these variants in transiently transfected HEK293
cells and found the levels are higher than in Ba/F3 but still
lower than the WT or the single N-glycosylation site defective
variants.
We next sought to determine the carbohydrate occupancy of
the four putative N-glycosylation sites. We performed EndoH (to
detect shifts in the case of high mannose glycosylated immature
receptors that are localized in ER or early Golgi) or PNGaseF (to
remove the N-glycans from the immature and mature proteins)
treatments on the transiently transfected HEK293 cell lysates.
We analyzed the enzymatic products in electrophoresis under
reducing conditions, and Western blotting for HA immunode-
tection. Because all these TpoR variants have only one putative
N-glycosylation site left and all of them showed a faster migration
inthepresenceof EndoHorPNGaseF(Figure4B)comparedwith
the untreated condition,we concluded that all of the possible sites
FIGURE3|E f f e c to fsingle N-glycosylation site removal on the
Tpo-dependent transcriptional activation of humanTpoR. (A) Ba/F3 or
Ba/F3-JAK2 cells expressing stably expressing each humanTpoR defective
in single N-glycosylation site [Δ (1), Δ (2), Δ (3), Δ (4)] were starved 3h in
RPMI medium +1mg/ml BSA and electroporated with the luciferase
reporters pGRR5-luc and pRLTK-luc.The cells were stimulated with 50ng
Tpo/ml or left unstimulated for 2h. Upon treatment the cells were lysed and
their luminescence recorded. Results are the mean±variation of triplicate
samples. One of three independent experiments is depicted.The t-test
showed statistically signiﬁcant differences for theTpo-dependent
transcriptional levels of theTpoR mutants when compared with the WT
TpoR (p <0.05 for all theTpoR variants). Of importance, when
Tpo-dependent Δ (1)TpoR transcriptional activity in the stimulated condition
was compared with the transcriptional activity of the stimulated WTTpoR,
the p value equaled 0.0086. (B) Ba/F3 stably transduced cells for each of
theTpoR variants [Δ (1), Δ (2), Δ (3), and Δ (4)] were washed three times
and seeded in 96-well plates at a density of 3,000 cells/well.The cells were
stimulated with 5ngTpo/ml, or with 5ng IL3/ml or left unstimulated during
72h. After 72h, the proliferation of the cells was determined by the DNA
synthesis assay reﬂected by the measurements of the thymidine
incorporation as described in Experimental procedures. Results are the
mean±variation of triplicate samples. One of three independent
experiments is depicted.The t-test showed signiﬁcant differences between
theTpo-dependent proliferations level of Δ (1)TpoR (p =0.0001) and Δ (2)
TpoR (p =0.0019) when compared with WTTpoR.
could be N-glycosylated. Thus sites 1, 2, 3, and 4 at Asn residues
117,178,298,and 358,respectively,are fully occupied.
The results from the enzymatic assessment of these TpoR vari-
ants on transiently transfected HEK293 cell lysates showed that
thereisveryloworabsentEndoHresistantband(maturereceptor,
cellsurfacelocalizedreceptor)whencomparedwiththeWTTpoR
(Figure 4B), supporting the observation of the ﬂow cytometry
results of Figure 4A.
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FIGURE4|E f f e c to fmultiple N-glycosylation sites removal on the cell
surface levels and function of humanTpoR. (A) Sorted Ba/F3 parental or
Ba/F3-JAK2 cells, expressingTpoR variants defective in three
N-glycosylation sites [Δ (123), Δ (124), Δ (134), Δ (234)] were tested for cell
surface levels using anti-HA antibody based ﬂow cytometry. Similar results
were obtained in two independent experiments, on two different cell lines
obtained for eachTpoR variant. For the Ba/F3 cells, the t-test showed
statistically signiﬁcant differences between Δ (123)TpoR (p =0.0019), Δ
(124)TpoR (p =0.0036), Δ (134)TpoR (p =0.0016), and Δ (234)TpoR
(p =0.0086) when compared with WTTpoR. (B) HEK293 cells were seeded
in 6-well plates and transiently transfected with 3μg of each of the indicated
TpoR variants.Twenty-four hours post-transfection cells were lysed and
treated with EndoH or PNGaseF or left untreated during 16h at 37˚C.The
digestion products were subjected to Western blot analysis. Membranes
were probed with anti-HA and anti-β-actin. Similar results were obtained in
two different experiments. (C) A pool of each cell line used in (A) was
treated at 37˚C with 50μg/ml cycloheximide (CHX) over different time
periods then lysed.The lysates were analyzed forTpoR variants stability
using anti-HA and normalized by anti-β-actin Western blotting. (D) Ba/F3 or
Ba/F3-JAK2 cells stably expressing each humanTpoR defective in three
N-glycosylation sites were starved 3h in RPMI medium +1mg/ml BSA and
electroporated with the pGRR5-luc and pRLTK-luc reporters.The cells were
stimulated with 50ngTpo/ml or left unstimulated 2h at 37˚C. Upon
treatment, the cells were lysed and their luminescence recorded. Results
are the mean±variation of triplicate samples. One of three independent
experiments is depicted.The t-test showed statistically signiﬁcant
differences forTpo-dependent transcriptional activity levels of the all the
TpoR variants, when compared with theWTTpoR (all the p values<0.0001).
To test the stability of TpoRs defective in multiple N-
glycosylation sites, we used stably transduced Ba/F3 cells with
each of the mutants and treated the cells with CHX over different
time periods. A very unstable pattern was observed for the three
N-glycosylation mutated variants (Figure 4C), indicating that
N-glycosylation exerts a protective action on TpoR stability.
Frontiers in Endocrinology | Molecular and Structural Endocrinology November 2011 | Volume 2 | Article 71 | 6Albu and Constantinescu N-glycosylation controlsTpoR surface localization
Wenexttestedinamoresensitiveassay,theabilityoftheseTpoR
variants to localize at the cell surface and to bind Tpo. Compared
with the WT, a dramatic decrease of JAK2–STAT transcriptional
activityforthesemutantswasobservedinstablytransducedBa/F3
orBa/F3-JAK2cellmodels(Figure4D).Inthecaseof Δ(123)and
Δ (234) the Tpo-dependent JAK2–STAT transcriptional activity
was decreased compared with the WT but higher than in the
case of Δ (124) and Δ (134) variants. We further tested the
same mutants in transiently transfected HEK293 cells (see below
Figure 6), but this difference between the mutants defective in
three glycosylation sites was not statistically signiﬁcant, suggest-
ing that it might either reﬂect cell type speciﬁc differences, or be
relevant at the lower stable expression levels achieved in the Ba/F3
system after sorting. These results pointed to the ﬁrst (Asn117)
or the last N-glycosylation site (Asn358) being important, for cell
surface localization (Figure 4A) or stability (Figure 4C) in Ba/F3
cells.
MAJOR IMPAIRMENT OF TpoR CELL SURFACE LOCALIZATION AND
ACTIVITY BY REMOVAL OF ALL N-GLYCOSYLATION SITES
Although the removal of three N-glycosylation sites dramatically
affected the cell surface localization and Tpo-dependent cell sig-
naling in Ba/F3 cells, we also wanted to test the TpoR variant
lackingallofthefourputativeN-glycosylationsites,Δ(1234).This
variantwascompletelyabsentfromthecellsurfacebyﬂowcytom-
etrybothinBa/F3orBa/F3overexpressingJAK2(Figure5A).Our
preliminary observation is that, for a cell surface level detectable
by ﬂow cytometry, at least one N-glycosylation site needs to be
glycosylated (Figures 4A,D).
Due to the fact the Δ (1234) TpoR was not detected at the
cell surface, we tested its degradation features compared with
the WT. We performed Western blot on the lysates of Ba/F3
and Ba/F3-JAK2 cell lines stably transfected with this mutant
or the WT TpoR. Before lysis, these cells were incubated 3h
at 37˚C with 50μg/ml cycloheximide (to block protein synthe-
sis) and proteasome inhibitor MG132 (10μM) or with 50μg/ml
cycloheximide and lysosome inhibitors (200μM chloroquine or
10μg/ml leupeptin). We observed a stabilization effect due to
the blocking of the proteasomal degradation (Figure 5B). Thus,
the TpoR variant lacking all four putative N-glycosylation sites
[Δ (1234)] is a very unstable protein that can be stabilized
by blocking proteasome-mediated degradation. It is very likely
that this mutant is an ER-associated degradation (ERAD) sub-
strate, but future analysis will be needed to demonstrate this
hypothesis.
The removal of all the N-glycosylation sites [Δ (1234) TpoR]
dramatically affected the STAT transcriptional activity in stably
transfected Ba/F3 and Ba/F3-JAK2 cell lines, compared with WT
TpoR (Figure 5C). This result was expected, because the cell
surface level of this mutant was undetectable by ﬂow cytome-
try in Ba/F3 cells. We also tested the Tpo-dependent cell growth
of these stable cell lines in a more sensitive assay (thymidine
incorporation), conﬁrming the data obtained in the luciferase
assay. We could not detect any Tpo-dependent growth even in
the presence of high Tpo levels (10ng Tpo/ml; Figure A1 in
Appendix).
THE DEFECTIVE N-GLYCOSYLATION VARIANTS ARE ABLE TO ACTIVATE
Tpo-DEPENDENT STAT ACTIVITY IN OVEREXPRESSION CONDITIONS IN
HEK293 AND γ2A CELLS
In order to assess whether the TpoR variants that exhibit defec-
tive localization and stability [Δ (123), Δ (124), (Δ (134), Δ
(234)] or [Δ (1234)] are able to bind Tpo and activate Tpo-
dependent signaling pathways, we tested all the TpoR variants in
an overexpression cell system.
In transiently transfected γ2A or HEK293 cells, in the case of
single N-glycosylation site [Δ (1),(Δ (2),(Δ (3),Δ (4)] defective
variants, there was no difference in the Tpo-dependent JAK2–
STAT transcriptional activity when compared with theWT recep-
tor(Figure6).Inthecaseof mutationof multipleN-glycosylation
sites [Δ (124), Δ (134), Δ (234)], their Tpo-dependent JAK2–
STAT transcriptional activity in transiently transfected was lower
than that of WT TpoR (Figure 6). Mutant Δ (124) was similar
to Δ (134) with respect to transcriptional activity in γ2A cells
(data not shown). For the mutant Δ (1234) TpoR, removal of
all N-glycosylation sites led to a signiﬁcantly decreased, but still
detectable, level of transcriptional activity in response to Tpo
(Figure 6). These data suggest that overexpression conditions
allow for some cell surface localization, which is sufﬁcient to sup-
portaresponsetoTpoligandintheverysensitiveluciferaseassays.
Importantly,these data indicate that the receptor mutants are not
misfolded and, once localized on the surface, they can bind Tpo.
DISCUSSION
OurmajorﬁndingisthatN-glycosylationsitesontheextracellular
TpoR domain exert essential regulatory roles on TpoR cell surface
localization and function. Using a combination of mutagenesis
and biochemistry approaches in stably transduced hematopoietic
cellsandinseveralothercelllines,weshowthatthefoursitesexert
positive and negative roles on receptor trafﬁc, that at least one
glycosylation site is essential for cell surface transport, and that
exit from ER and stability are regulated by N-glycosylation.When
three of the four N-glycosylation sites were mutated, we could
demonstratethattheremainingN-glycosylationsitewasoccupied.
Previous data presented a differential role of the N-glycans for
different cytokine receptor trafﬁc, ligand binding, and function
(Ding et al., 1995; Buteau et al., 1998; Bolander, 1999; Niu et al.,
2000; Kamikubo et al., 2008; Waetzig et al., 2010). There are no
availablestudiesontheimportanceof thecarbohydrategroupson
the cell surface expression and function of human TpoR. In order
to perform our study,we constructed nine human TpoR variants,
defectiveinone,three,orfouroutof fourputativeN-glycosylation
sites located of the extracellular domain. Taking into account that
TpoRisveryimportantforthecellsofhematopoieticlineage,most
of theresultsof thisstudywereobtainedinBa/F3andBa/F3-JAK2
cell lines.
Theﬁrstquestionweaskedwaswhetherthephysiologichuman
TpoR cell surface localization requires the occupancy of a speciﬁc
N-glycosylationsitefromthefourputativeones(Figure1A).None
of the four single sites was critical for cell surface localization, for
Tpo binding or for Tpo-dependent activation of the JAK2–STAT
signalpathway.Nevertheless,theTpoRmutantlackingtheﬁrstN-
glycosylationsite(Asn117)isthemostinterestinganditconstantly
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FIGURE 5 | Removal of all four N-glycosylation sites dramatically affects
the cell surface localization of humanTpoR in Ba/F3 cells. (A) Ba/F3 or
Ba/F3-JAK2 cells stably expressing the WTTpoR or the variant of the receptor
defective in all four N-glycosylation sites [Δ (1234)] were tested for cell
surface levels using anti-HA antibody based ﬂow cytometry. Similar results
were obtained in ﬁve independent experiments, on two different cell lines
obtained for the Δ (1234) variant (p <0.0001). Right panel of the (A) shows a
Western blot of the cells used in the experiment, probing the receptor with
anti-HA antibodies, the murine JAK2 WT with anti-JAK2 antibodies and using
anti-β-actin as a control. (B) Ba/F3 or Ba/F3-JAK2 cells used in (A) were tested
for the contribution of the proteasome- or lysosome-mediated degradation of
theTpoR N-glycosylation defective mutant Δ (1234) versusWT.The cells were
incubated 3h at 37˚C with 50μg/ml cycloheximide and proteasome inhibitor
MG132 (10μM) or with 50μg/ml cycloheximide and lysosome inhibitors
(200μM chloroquine or 10μg/ml leupeptin). Control cells were kept untreated
to have 100% protein expression. Cells were lysed and analyzed by Western
blotting with antibodies against HA for the levels ofTpoR and anti-β-actin as a
loading control. (C) Pools from the same cell lines used in (A,B) were starved
3h in RPMI medium +1mg/ml BSA and electroporated with pGRR5-luc and
pRLTK-luc reporters.The cells were also stimulated withTpo or left
unstimulated during 2h at 37˚C. Upon treatment the cells were lysed and
their luminescence recorded. Results are the mean±variation of triplicate
samples. One of three independent experiments is depicted.The t-test
showed statistically signiﬁcant differences between theTpo-dependent
transcriptional activities level of the Δ (1234)TpoR and that of WTTpoR
(p <0.0001 for both Ba/F3 and Ba/F3-JAK2 cell lines).
presents striking differences compared with the WT TpoR. The
cellsurfacelevelof Δ(1)TpoRwasdecreasedinBa/F3andBa/F3-
JAK2 cells (Figure 2A). Compared with the WT, the JAK–STAT
transcriptional activity of this variant was also decreased in Ba/F3
and Ba/F3-JAK2 (Figure 3A), and we consequently observed a
decrease in the Tpo-dependent cell proliferation of Ba/F3 sta-
bly transduced with this receptor, compared with Ba/F3 stably
transduced with WT TpoR (Figure 3B). Alignments of TpoR
from different species (Figure 1A) pointed out that this ﬁrst
N-glycosylation site of human TpoR is highly conserved between
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FIGURE 6 | HumanTpoR mutants defective in N-glycosylation sites are
able, in overexpression conditions, to supportTpo-dependent STAT3 and
STAT5 transcriptional activities. (A) HEK293 cells were plated in 24-well
plates the day before transfection.The cells were co-transfected with
plasmids encoding for each of theTpoR variants, the pLHRE-luc and
pRLTK-luc reporters, and JAK2 WT. Cells were lysed 24h after treatment in
100 μl1 × passive lysis buffer and luminescence values were recorded.The
experiment was independently performed three times and the presented
result represents±variation of triplicate samples.The t-test showed that the
unstimulated condition is signiﬁcantly different from the stimulated condition
for the Δ (1234)TpoR (p =0.0058). (B), JAK2-deﬁcient γ2A cells were plated
in 24-well plates a day before transfection.The cells were co-transfected with
plasmids encoding for each of theTpoR variants, the pGRR5-luc and
pRLTK-luc reporters, and JAK2 WT. Four hours post-transfection cells were
stimulated or left unstimulated. Cells were lysed 24h after treatment in 100μl
1× passive lysis buffer and luminescence values were recorded.The
experiment was independently performed two times and the result presented
represents±variation of triplicate samples.
species. We hypothesize that occupancy of this site is important
but not crucial for TpoR cell surface expression. Rather, this car-
bohydrate group might exert a ﬁne control on the cell surface
level of TpoR. Consistent with our results, previous observations
found that cell surface levels of TpoR are important for setting
the correct blood platelet production. Insufﬁcient expression of
TpoR at the surface of late megakaryocytes and of platelets can
lead to the unexpected phenotype of thrombocytosis, since Tpo
ligand was not properly removed from circulation and it could
still stimulate early megakaryocyte proliferation and differentia-
tion (Lannutti et al., 2009; Tiedt et al., 2009). Moreover, TpoR
defective N-glycosylation and impaired cell surface localization
was detected in the megakaryocytes and platelets of Polycythemia
Verapatients(Moliternoetal.,1998;MoliternoandSpivak,1999).
In contrast to the results with Δ (1) TpoR, the Δ (3) TpoR
mutant was localized at the cell surface to higher extents than the
WT TpoR and showed enhanced maturation and activity. This
glycosylation site is not conserved in rodents. Interestingly, its
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presence limits receptor function in human TpoR. It is interest-
ing to note that normal platelet levels are higher in mice than in
humans. One possibility is that absence of this site allows higher
levelsofplateletproductioninmice.Furtherstudiesusingaknock-
inapproachof amurineTpoRcontainingthisN-glycosylationsite
could answer this question.
Several mutations in the ﬁrst ﬁve exons coding for the ﬁrst
cytokinereceptorhomologydomainhavebeendescribedtoaffect
thecellsurfacedisplayof TpoR.Mutationslocatedaroundresidue
Asn117, possibly affecting the N-glycosylation pattern, are at
the basis of two types of hematological diseases, with oppo-
site pathologies: congenital amegakaryocytic thrombocytopenia
(CAMT; Ballmaier et al., 2001; Germeshausen et al., 2006; Tijssen
et al., 2008; Fox et al., 2009) and familial thrombocytosis (FT;
Moliternoetal.,2004;El-HarithEletal.,2009;TeoﬁliandLarocca,
2011;Figure1B).ExtracellulardomainmutationsinCAMTabol-
ishcellsurfacereceptorlocalization,whileFTextracellulardomain
mutations severely impair, though do not abolish, cell surface
localization.Forthelatter,sinceTpoRonplateletsperformsclear-
ance of Tpo from the circulation, low platelet TpoR levels are
associatedwithincreasedlevelsofTpointhebloodandinthebone
marrow,asituationsimilartotheonereportedwhenTpoRexpres-
sion levels are decreased at the late megakaryocyte and platelet
levels (Lannutti et al., 2009; Tiedt et al., 2009). Our results show
that Asn117 occupancy is able to control the cell surface expres-
sion of human TpoR and consequently its availability for Tpo.
We hypothesize that this ﬁrst N-glycan is important for efﬁcient
cell surface localization and that mutations around Asn117 might
eitherimpacttheefﬁciencyof glycosylationof thissite,oritsinter-
action with ER chaperone proteins. More studies are required
in order to determine which scenario is true for each mutation
detected in humans.
Amajorﬁndingof ourstudyisthatremovalof threeoutof four
N-glycosylation sites did not abolish, but signiﬁcantly decreased,
the cell surface localization, and activity of TpoR (Figure 4). In
Ba/F3 cell lines, at least one N-glycosylation site of human TpoR
needs to be occupied in order to have detectable cell surface levels
and Tpo-dependent gene transcription. Neither JAK2 nor TYK2
were able to restore to normal the cell surface level of these vari-
ants (Figure 4). JAK2 levels differ between the cell types of the
hematopoietic lineage (Dalal et al., 1998) and JAK2 was shown to
promote WT TpoR trafﬁc to the cell surface (Royer et al., 2005).
Interestingly, in this study we show that the ability of JAK2 to
promote cell surface localization of TpoR requires a normal N-
glycosylation,with more than one site occupied. It is possible that
JAK2 is not able to rescue the cell surface localization of TpoRs
that do not acquire a speciﬁc N-glycosylation pattern. In any case,
our data suggest that JAK2 binding to the cytosolic juxtamem-
brane region induces an inside-out conformational change that
must be sensed by the extracellular domain Asn117. More studies
arerequiredinordertodeterminewhetherN-glycosylationplaces
TpoR in a particular region of the ER, or facilitates interaction
with export proteins. Such studies are currently underway.
The analysis of the cell surface localization of TpoRs with dif-
ferent N-glycosylation patterns is very important, as one of the
essential functions of the N-glycans is to secure efﬁcient pro-
tein production. The N-glycosylation sites are crucial for the
interactionofthereceptorwiththelectin-likechaperonesfromER,
in the process of proper folding. The calnexin–calreticulin quality
control cycle was previously described, in which these two chap-
erones are acting in the initial steps of glycoprotein folding. Pro-
longedinteractionwithcalnexin,duetoinefﬁcientfolding,results
in the substrate being directed to the proteasome for degradation.
WehypothesizethattheTpoRmutantsreportedindifferenthema-
tological diseases and that are defective in cell surface localization,
could be retained in early folding compartments due to this pro-
longed interactions with the lectin-like chaperones. In this model,
N-glycans are a limiting event for proper cell surface localization.
The nature and expression levels of chaperones differ between cell
types or stages of differentiation, thus possibly explaining why a
particular mutant can be localized at the surface of some progen-
itors and not others. Future experiments will have to address the
importance of N-glycans for human TpoR interactions with the
ER chaperones. Besides its key role in Tpo-dependent signaling,
JAK2 acts as a cytosolic chaperone that increases the receptor traf-
ﬁctocellsurface(Royeretal.,2005),butitispossiblethatthemain
determinants that govern the ER to plasma membrane trafﬁc of
human TpoR to be located in ER and to be inﬂuenced by receptor
N-glycosylation pattern.
Wealsoobservedinourstudythattheremovalof allfourputa-
tive N-glycosylation sites dramatically affects cell surface localiza-
tion of TpoR and Tpo-dependent cell proliferation in the Ba/F3
cell model (Figure 5 and data not shown). This observation sup-
ports the notion that N-glycosylation is crucial for the ER to cell
surface trafﬁc of TpoR. In this model, the presence of N-glycans
promotes trafﬁc of the receptor to the cell surface. JAK2 was not
able to promote cell surface localization of the mutant defective
in all N-glycosylation sites. Along with the results obtained with
single and multiple defective glycosylation sites, this result again
points to an inside-out conformational change induced by JAK2
binding to the cytosolic domain that is sensed by the extracellular
domain via N-glycosylation sites.
Finally,ourresultsshowedthatallthereceptorsdefectiveindif-
ferent combinations of N-glycosylation sites were able to support
Tpo-dependenttranscriptionalactivityinanoverexpressedsystem
(Figure6),thusindicatingthatdefectiveN-glycosylationdoesnot
simplyinducemisfoldingandthatN-glycosylationdefectiveTpoR
mutantsareabletobindTpo,oncetheyreachthecellsurface.This
is quite important and it can serve as a starting point for targeting
ER-associated folding machinery in diseases with TpoR mutants
blocked in this compartment, as receptors could be functional
once they escape from the ER and localize at the cell surface.
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APPENDIX
FIGUREA1 | Removal of all four N-glycosylation sites dramatically
affects theTpo-dependent cell proliferation of humanTpoR in Ba/F3
and Ba/F3-JAK2 cells. Ba/F3 and Ba/F3-JAK2 cells stably expressingWT or
Δ (1234) humanTpoR were washed 3 times and seeded in 96-well plates at
a density of 3,000 cells/well.The cells were stimulated with differentTpo
concentrations, or with 5ngIL3/ml or left unstimulated during 72h. After
72h, cell proliferation was determined by the DNA synthesis assay
reﬂected by the measurements of the thymidine incorporation as described
in Experimental procedures. Results are the mean±variation of triplicate
samples. One of two independent experiments is depicted.
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